A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.

ABSTRACT:

Background

Several programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) antibodies have been approved for cancer treatment worldwide. Their pharmacokinetic and pharmacodynamic characteristics have been reported mainly in western countries, but related data in Chinese patients are limited. This study was conducted to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of an anti-PD-1 antibody, toripalimab, in Chinese patients.

Methods

A single-center phase I study was conducted in Sun Yat-sen University Cancer Center. Eligible patients were adults with histologically confirmed, treatment-refractory, advanced, solitary malignant tumors. Toripalimab was intravenously infused every 2 weeks in dose-escalating cohorts at 0.3 mg/kg, 1 m

SUBMITTER: Wei XL 

PROVIDER: S-EPMC7427305 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature